DJIA 17,031.14 43.63 0.26%
NASDAQ 4,518.90 -48.70 -1.07%
S&P 500 1,984.13 -1.41 -0.07%
market minute promo

4.88 -0.28 (-5.43%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $4.88 -5.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.15
Previous Close $5.16
Daily Range $4.50 - $5.16
52-Week Range $4.50 - $7.82
Market Cap $598.0M
P/E Ratio -6.29
Dividend (Yield) $0.00 (0.0%)
Volume 13,341,285
Average Daily Volume 4,056,232
Current FY EPS -$0.35





Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary Rss Feed

2 New Diet Drugs Coming Soon?

Orexigen Therapeutics and Novo Nordisk are close to bringing new diet drugs to market. But will doctors prescribe them?

Orexigen Falls After Approval - Why?

Arena And Vivus Ruined The FDA Approval Run Up For Orexigen

Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog

Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

Orexigen: Poised To Grab A Large Part Of The Weight Loss Market

Orexigen Therapeutics (OREX) Marked As A Dead Cat Bounce Stock

Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen Therapeutics, Inc. Be Afr

A new weight loss pill from Orexigen will face stiff competition from Arena's Belviq and may soon have to compete against Novo Nordisk's Saxenda.

FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug

Orexigen and Takeda's Contrave has the right balance of efficacy and safety.

Sector Update: Health Care Stocks Sit Out Late Rise For Stocks; Orexigen Slammed After FDA 'Black La

Sector Update: Health Care Stocks Sit Out Late Rise For Stocks; Orexigen Slammed After FDA 'Black Label'

See More OREX News...

OREX's Top Competitors

OREX $4.88 (-5.43%)
Current stock: OREX
AMGN $137.97 (0.06%)
Current stock: AMGN
GILD $100.99 (-2.58%)
Current stock: GILD
BIIB $320.12 (-1.01%)
Current stock: BIIB